ストックスクリーナーアプリを入手
11.80
0.59%
0.03
前日終値:
$11.77
開ける：
$11.84
24時間の取引高:
261.89K
Relative Volume:
0.33
時価総額：
$646.31M
収益：
$27.46M
当期純損益:
$-46.05M
株価収益率:
-9.1473
EPS:
-1.29
ネットキャッシュフロー:
$-33.83M
1週間 パフォーマンス:
-6.48%
1か月 パフォーマンス:
+29.40%
6か月 パフォーマンス:
+47.26%
1年 パフォーマンス:
+89.74%
1日の値動き範囲:
$11.67
$11.87
1週間の範囲:
$11.49
$12.80
52週間の値動き範囲:
$5.45
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
名前
Zevra Therapeutics Inc
セクター
電話
(321) 939-3416
住所
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
ZVRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
11.82 | 633.19M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.18 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.72 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.85 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
589.22 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.24 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-08 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 開始されました | Guggenheim | Buy |
| 2024-09-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-24 | 繰り返されました | Maxim Group | Buy |
| 2024-04-02 | 繰り返されました | Maxim Group | Buy |
| 2024-03-12 | 開始されました | William Blair | Outperform |
| 2023-03-17 | 開始されました | Maxim Group | Buy |
すべてを表示
Zevra Therapeutics Inc (ZVRA) 最新ニュース
Is Zevra Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - jammulinksnews.com
What drives Zevra Therapeutics Inc. stock priceAccelerated capital growth - jammulinksnews.com
What analysts say about Zevra Therapeutics Inc. stockFree Capital Efficiency Planning - jammulinksnews.com
Zevra Therapeutics Inc. Stock Analysis and ForecastFree Investment Timing Strategies - jammulinksnews.com
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® - GlobeNewswire
Zevra Therapeutics: Promising Growth Driven by Miplyffa Success and Strategic Focus on Rare Diseases - TipRanks
ZVRA Showcases Key Findings on MIPLYFFA and OLPRUVA at Genetics - GuruFocus
Zevra Therapeutics Highlights Research on MIPLYFFA® and OLPRUVA® at 42nd Annual SERGG Meeting - Nasdaq
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
William Blair Issues Optimistic Forecast for ZVRA Earnings - Defense World
Zevra Therapeutics' MIPLYFFA: A Paradigm Shift in Rare Disease Treatment - AInvest
Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice - Yahoo Finance
5 Small Drug Stocks To Buy Amid Trump's New Tariff Threats - Barchart.com
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail
Zevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type C - Nasdaq
Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism - The Manila Times
Breakthrough: New Clinical Data Shows MIPLYFFA Halts Rare Brain Disease Progression for 5 Years - Stock Titan
Niemann-Pick Disease Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - The Globe and Mail
ZVRA Publishes Positive Long-term Results for Arimoclomol in NPC Treatment | ZVRA Stock News - GuruFocus
Why Zevra Therapeutics Inc. stock attracts strong analyst attentionEarly Buy Suggestion - newser.com
What makes Zevra Therapeutics Inc. stock price move sharplyHigh Yield Stock Selection - Newser
Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know - Yahoo Finance
Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA) - Yahoo Finance
How Zevra Therapeutics Inc. stock performs during market volatilityBreakout Momentum Alerts - Newser
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Cantor Fitzgerald Issues Positive Outlook for ZVRA Earnings - Defense World
Cantor Fitzgerald Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - Defense World
Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street Zen - Defense World
Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) - GlobeNewswire
Zevra(ZVRA) Soars 4.41% on Phase 2 Trial, Strategic Collaboration - AInvest
ZVRA Highlights MIPLYFFA Data at Niemann Pick Conference | ZVRA Stock News - GuruFocus
Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference | ZVRA Stock News - GuruFocus
Zevra Therapeutics Showcases MIPLYFFA® Data at National Niemann Pick Disease Foundation Conference - Nasdaq
Zevra Therapeutics presents MIPLYFFA data at NNPDF Conference, FDA-approved NPC treatment. - AInvest
MIPLYFFA Clinical Data Shows Disease-Halting Results for Niemann-Pick Disease | ZVRA Stock News - Stock Titan
Zevra Therapeutics Inc (ZVRA) 財務データ
収益
当期純利益
現金流量
EPS
3.28%
1.50%
大文字化:
|
ボリューム (24 時間):